Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study

被引:38
作者
Constantin, Tina [1 ]
Tangpricha, Vin [1 ,2 ]
Shah, Reshma [1 ]
Oyesiku, Nelson M. [3 ]
Ioachimescu, Octavian C. [2 ,4 ]
Ritchie, James [5 ]
Ioachimescu, Adriana G. [1 ,3 ]
机构
[1] Emory Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30307 USA
[2] Atlanta VA Med Ctr, Decatur, GA 30033 USA
[3] Emory Univ, Dept Neurosurg, Sch Med, Atlanta, GA 30307 USA
[4] Emory Univ, Div Pulm Allergy Crit Care & Sleep Med, Dept Med, Sch Med, Atlanta, GA 30307 USA
[5] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30307 USA
关键词
GROWTH-FACTOR-I; GH-DEFICIENT ADULTS; VERTEBRAL FRACTURES; MINERAL DENSITY; TRABECULAR BONE; FOLLOW-UP; IGF-I; HORMONE; METABOLISM; HOMEOSTASIS;
D O I
10.1210/jc.2016-3693
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Acromegaly has been associated with calcium-phosphate and bone turnover alterations. Controlled studies of these interactions are sparse. Objective: To evaluate calcium and bone metabolism in active and treated acromegaly. Design/Setting/Patients:We conducted a controlled, prospective study at a tertiary referral center. We studied 22 patients with acromegaly referred for surgical or medical therapy (ACM) and 22 with nonfunctioning pituitary adenomas referred for surgery (control). Main OutcomeMeasures:Calcium (serum and urine), phosphorus, parathyroid hormone (PTH), 25-hydroxy- and 1,25-dihydroxy-vitamin D, bone turnover markers [serum C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP)], and cytokines [receptor activator of nuclear factor kappa B ligand (RANK-L) and osteoprotegerin (OPG)] at baseline and 3 to 6 months after treatment. Results: At baseline, the ACM group had lower PTH levels than controls (36.3 +/- 13.9 pg/mL vs 56.0 +/- 19.9 pg/mL) and higher phosphorus (4.34 +/- 0.71 mg/dL vs 3.55 +/- 0.50 mg/dL) (P < 0.01). Groups had similar levels of serum and urine calcium and 25-hydroxy- and 1,25-dihydroxy-vitamin D. The ACM group had higher bone turnover markers than control; P1NP and CTX were strongly correlated (r(2) = 0.82, P < 0.05). CTX was dependent on age and disease group but not on sex or gonadal status. After treatment of acromegaly, serum calcium (9.52 +/- 0.43 mg/dL to 9.26 +/- 0.28 mg/dL), phosphorus (4.34 +/- 0.71 mg/dL to 3.90 +/- 0.80 mg/dL), and CTX (0.91 +/- 0.75 ng/mL to 0.63 +/- 0.68 ng/mL) decreased, while PTH increased (36.3 +/- 13.9 pg/mL to 48.9 +/- 16.7 pg/mL) (P < 0.01). 25-hydroxy-vitamin D, P1NP, and RANK-L/OPG ratio did not change significantly. Conclusions: Acromegaly patients exhibited PTH-independent calcium-phosphate alterations and enhanced coupled bone formation and resorption. Within 6 months of treatment, bone resorption decreased, whereas RANK-L/OPG changes were inconsistent.
引用
收藏
页码:2416 / 2424
页数:9
相关论文
共 31 条
[1]   Evidence for a Role of Prolactin in Calcium Homeostasis: Regulation of Intestinal Transient Receptor Potential Vanilloid Type 6, Intestinal Calcium Absorption, and the 25-Hydroxyvitamin D3 1α Hydroxylase Gene by Prolactin [J].
Ajibade, Dare V. ;
Dhawan, Puneet ;
Fechner, Adam J. ;
Meyer, Mark B. ;
Pike, J. Wesley ;
Christakos, Sylvia .
ENDOCRINOLOGY, 2010, 151 (07) :2974-2984
[2]   Acromegaly and bone disease [J].
Anthony, Jeremy R. ;
Ioachimescu, Adriana G. .
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (06) :476-482
[3]   Effects of short-term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults [J].
Bianda, T ;
Glatz, Y ;
Bouillon, R ;
Froesch, ER ;
Schmid, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01) :81-87
[4]   ROLE OF PITUITARY-HORMONES IN REGULATING RENAL VITAMIN-D METABOLISM IN MAN [J].
BROWN, DJ ;
SPANOS, E ;
MACINTYRE, I .
BRITISH MEDICAL JOURNAL, 1980, 280 (6210) :277-278
[5]   Long-term treatment of acromegaly with lanreotide: Evidence of increased serum parathormone concentration [J].
Cappelli, C ;
Gandossi, E ;
Agosti, B ;
Cerudelli, B ;
Cumetti, D ;
Castellano, M ;
Pirola, I ;
De Martino, E ;
Rosei, EA .
ENDOCRINE JOURNAL, 2004, 51 (06) :517-520
[6]   Progression of Vertebral Fractures Despite Long-Term Biochemical Control of Acromegaly: A Prospective Follow-up Study [J].
Claessen, K. M. J. A. ;
Kroon, H. M. ;
Pereira, A. M. ;
Appelman-Dijkstra, N. M. ;
Verstegen, M. J. ;
Kloppenburg, M. ;
Hamdy, N. A. T. ;
Biermasz, N. R. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (12) :4808-4815
[7]   Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas [J].
Dekkers, O. M. ;
Pereira, A. M. ;
Romijn, J. A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10) :3717-3726
[8]   THE SHORT AND LONG-TERM EFFECTS OF OCTREOTIDE ON CALCIUM HOMEOSTASIS IN PATIENTS WITH ACROMEGALY [J].
FREDSTORP, L ;
PERNOW, Y ;
WERNER, S .
CLINICAL ENDOCRINOLOGY, 1993, 39 (03) :331-336
[9]   Impact of growth hormone hypersecretion on the adult human kidney [J].
Grunenwald, Solange ;
Tack, Ivan ;
Chauveau, Dominique ;
Bennet, Antoine ;
Caron, Philippe .
ANNALES D ENDOCRINOLOGIE, 2011, 72 (06) :485-495
[10]   CALCIUM AND PHOSPHATE-METABOLISM IN ACROMEGALY [J].
HALSE, J ;
HAUGEN, HN .
ACTA ENDOCRINOLOGICA, 1980, 94 (04) :459-467